Figure 2. Viability decline and cell cycle retardation of Tetracaine-treated HCEP cells.

A: MTT assay. The cell viability of Tetracaine-treated HCEP cells in each group was expressed as percentage (mean±SD) of 490 nm absorbance compared to its corresponding control (n=3). B: FCM with propidium iodide (PI) staining. G1 phase arrest of HCEP cells exposed to 0.3125 g/L Tetracaine was shown. The number of HCEP cells in different cell cycle phase in each group was expressed as percentage (mean±SD) of its total cell number (n=3), respectively. ^aP<0.05, ^bP<0.01 versus control.